Clarametyx Biosciences, Columbus, OH, USA
http://www.clarametyx.com/

CMTX-301

Clarametyx is developing CMTX-301, a pathogen-agnostic anti-biofilm vaccine candidate designed to prevent bacterial biofilm formation and allow the body’s natural immune response to clear infections. If successful, immunization with CMTX-301 to prevent the occurrence of biofilm-associated infections may decrease the need for antibiotic therapy and thus decrease the threat of resistance development.

Bacterial biofilms are the bacteria’s greatest defense mechanism against host immune effectors and antibiotics, responsible for 80% of bacterial infections, and a known contributor to antimicrobial resistance. Biofilms represent a significant challenge to delivering safe effective medical procedures for patients increasing bacteria tolerance to antibiotics up to 1000-fold.

Biofilms enable bacteria to infect medical devices and human tissues shielding bacteria from natural clearance mechanisms. Bacterial biofilms are increasingly recognized to be involved in clinical infections in many body systems including the auditory, the cardiovascular, the digestive, the integumentary, the reproductive, the respiratory, and the urinary system. Biofilms initially formed on medical implants, such as heart valves or joint prostheses, or on medical devices such as catheters, can lead to bloodstream infections which are associated with significant morbidity and mortality. Immunization with CMTX-301 targets the critical structural lattice of the biofilm, preventing the formation of the biofilm and thereby reduces and clears bacterial infections without the use of antibiotics.

Current Development Stage: Lead Optimization

CARB-X Investment: US$2.6M

Initial CARB-X Investment Date: January 7, 2025